WEREWOLF THERAPEUTICS, INC. Operating Expenses
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Operating Expenses of $13.84 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $13.84M, a 21.09% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $13.27M, a 26.24% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $9.42M, a 53.72% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $15.73M, a 8.16% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating expenses for fiscal 2023 was $60.45M, a 16.58% decline from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. operating expenses for fiscal 2022 was $72.46M, a 44.66% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. operating expenses for fiscal 2021 was $50.09M, a 123.56% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. operating expenses for fiscal 2020 was $22.40M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.84M S-4 · filed 2026-09-22 | $27.11M S-4 · filed 2026-09-22 | $36.53M derived: sum of 3 quarters · filed 2026-09-22 | $52.26M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $13.27M 10-Q · filed 2026-05-07 | $22.69M derived: sum of 2 quarters · filed 2026-09-22 | $38.41M derived: sum of 3 quarters · filed 2026-09-22 | $55.96M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $9.42M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $25.14M derived: sum of 2 quarters · filed 2026-09-22 | $42.69M derived: sum of 3 quarters · filed 2026-09-22 | $60.68M S-4 · filed 2026-09-22 |
| 2025-09-30 | $15.73M 10-Q · filed 2025-11-04 | $33.27M derived: sum of 2 quarters · filed 2026-09-22 | $51.26M 10-Q · filed 2025-11-04 | $71.61M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $17.54M S-4 · filed 2026-09-22 | $35.53M S-4 · filed 2026-09-22 | $55.88M derived: sum of 3 quarters · filed 2026-09-22 | $73.00M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $17.99M 10-Q · filed 2026-05-07 | $38.34M derived: sum of 2 quarters · filed 2026-09-22 | $55.46M derived: sum of 3 quarters · filed 2026-09-22 | $75.57M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $20.35M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $37.47M derived: sum of 2 quarters · filed 2026-09-22 | $57.58M derived: sum of 3 quarters · filed 2026-09-22 | $75.48M S-4 · filed 2026-09-22 |
| 2024-09-30 | $17.12M 10-Q · filed 2025-11-04 | $37.23M derived: sum of 2 quarters · filed 2025-11-04 | $55.13M 10-Q · filed 2025-11-04 | $69.59M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $20.10M 10-Q · filed 2025-08-14 | $38.01M 10-Q · filed 2025-08-14 | $52.47M derived: sum of 3 quarters · filed 2025-08-14 | $67.62M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $17.90M 10-Q · filed 2025-05-08 | $32.37M derived: sum of 2 quarters · filed 2025-05-08 | $47.52M derived: sum of 3 quarters · filed 2025-05-08 | $61.66M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $29.61M derived: sum of 2 quarters · filed 2025-03-11 | $43.76M derived: sum of 3 quarters · filed 2025-03-11 | $60.45M 10-K · filed 2025-03-11 |
| 2023-09-30 | $15.15M 10-Q · filed 2024-11-07 | $29.30M derived: sum of 2 quarters · filed 2024-11-07 | $45.98M 10-Q · filed 2024-11-07 | $66.44M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $14.15M 10-Q · filed 2024-08-08 | $30.84M 10-Q · filed 2024-08-08 | $51.30M derived: sum of 3 quarters · filed 2024-08-08 | $68.81M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $16.69M 10-Q · filed 2024-05-03 | $37.15M derived: sum of 2 quarters · filed 2024-05-03 | $54.66M derived: sum of 3 quarters · filed 2024-05-03 | $73.78M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $20.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $37.97M derived: sum of 2 quarters · filed 2024-03-07 | $57.09M derived: sum of 3 quarters · filed 2024-03-07 | $72.46M 10-K · filed 2024-03-07 |
| 2022-09-30 | $17.51M 10-Q · filed 2023-11-14 | $36.63M derived: sum of 2 quarters · filed 2023-11-14 | $51.99M 10-Q · filed 2023-11-14 | $69.88M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $19.12M 10-Q · filed 2023-08-10 | $34.49M 10-Q · filed 2023-08-10 | $52.37M derived: sum of 3 quarters · filed 2023-08-10 | $66.17M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $15.37M 10-Q · filed 2023-05-11 | $33.25M derived: sum of 2 quarters · filed 2023-05-11 | $47.05M derived: sum of 3 quarters · filed 2023-05-11 | $58.00M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $17.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $31.68M derived: sum of 2 quarters · filed 2023-03-23 | $42.63M derived: sum of 3 quarters · filed 2023-03-23 | $50.09M 10-K · filed 2023-03-23 |
| 2021-09-30 | $13.79M 10-Q · filed 2022-11-10 | $24.75M derived: sum of 2 quarters · filed 2022-11-10 | $32.20M 10-Q · filed 2022-11-10 | $39.59M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $10.96M 10-Q · filed 2022-08-11 | $18.41M 10-Q · filed 2022-08-11 | $25.80M derived: sum of 3 quarters · filed 2022-08-11 | $31.85M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $7.45M 10-Q · filed 2022-05-10 | $14.84M derived: sum of 2 quarters · filed 2022-05-10 | $20.90M derived: sum of 3 quarters · filed 2022-05-10 | $25.96M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $13.45M derived: sum of 2 quarters · filed 2022-03-24 | $18.51M derived: sum of 3 quarters · filed 2022-03-24 | $22.40M 10-K · filed 2022-03-24 |
| 2020-09-30 | $6.05M 10-Q · filed 2021-11-10 | $11.12M derived: sum of 2 quarters · filed 2021-11-10 | $15.01M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.07M 10-Q · filed 2021-08-12 | $8.96M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $3.89M 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |